valsartan has been researched along with Pulmonary Hypertension in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 5 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdul-Jawad Altisent, O; Barceló, E; Bayes-Genis, A; Casquete, D; Cediel, G; Codina, P; de la Espriella, R; Domingo, M; Gastelurrutia, P; Lupón, J; Nuñez, J; Pascual-Figal, DA; Ruiz-Cueto, M; Santesmases, J; Santiago-Vacas, E; Spitaleri, G; Vila, J; Zamora, E | 1 |
| Bin, J; Cao, S; Chen, L; He, M; Huang, X; Li, M; Liao, W; Liao, Y; Lin, H; Liu, C; Shen, M; Zheng, C | 1 |
| Blohm, JH; Brockmöller, J; Burgdorf, C; Hundack, L; Ivanoski, S; Januszewski, M; Remppis, BA | 1 |
| Choudhary, G; Clements, RT; Fernandez-Nicolas, A; Kue, NR; Mallem, K; Mancini, TJ; McCullough, DJ; Morrison, AR; Vang, A | 1 |
| Cheng, S; Hamilton, MA; Kittleson, MM; Solomon, SD; Wolfson, AM; Zern, EK; Zile, MR | 1 |
| Hu, J; Liu, S; Liu, W; Lu, S; Wang, Y; Wang, Z; Zeng, X | 1 |
| Chen, W; Dong, J; Gao, D; Guo, H; Lu, Y; Pan, X; Sun, Y; Xu, D; Xu, Y | 1 |
| Andersen, A; Andersen, S; Axelsen, JB; Bogaard, HJ; de Man, FS; Hyldebrandt, JA; Nielsen-Kudsk, JE; Nyengaard, JR; Ringgaard, S | 1 |
| Ambrosio, G; Anker, SD; Díez, J; Edelmann, F; Filippatos, GS; Fraser, AG; Gavazzi, A; Gheorghiade, M; Guazzi, M; Hummel, SL; Lam, CS; Levy, D; Maggioni, AP; Metra, M; Paulus, WJ; Pfeffer, MA; Pieske, BM; Senni, M; Smiseth, OA; Solomon, SD; Stewart Coats, AJ; Stough, WG; Tschöpe, C | 1 |
| Friedrich, D; Gortner, L; Herkenrath, P; Hoppe, B; Hünseler, C; Kattner, E; Körber, F; Lindner, U; Müller, A; Oberthuer, A; Paneitz, A; Roth, B; Schaible, T; Schmitt, K; Welzing, L | 1 |
1 review(s) available for valsartan and Pulmonary Hypertension
| Article | Year |
|---|---|
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.
Topics: Aminobutyrates; Anemia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Biphenyl Compounds; Cardiotonic Agents; Clinical Trials as Topic; Diabetic Angiopathies; Diuretics; Drug Combinations; Exercise Therapy; Heart Failure; Homeostasis; Humans; Hypertension, Pulmonary; Iron Deficiencies; Mineralocorticoid Receptor Antagonists; Molecular Targeted Therapy; Obesity; Observational Studies as Topic; Patient Selection; Phenotype; Phosphodiesterase 5 Inhibitors; Sodium Channel Blockers; Stroke Volume; Tetrazoles; Valsartan; Vascular Stiffness | 2014 |
9 other study(ies) available for valsartan and Pulmonary Hypertension
| Article | Year |
|---|---|
Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension.
Topics: Aminobutyrates; Arterial Pressure; Biphenyl Compounds; Heart Failure; Humans; Hypertension, Pulmonary; Neprilysin; Quality of Life; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Valsartan | 2022 |
LCZ696 (sacubitril/valsartan) inhibits pulmonary hypertension induced right ventricular remodeling by targeting pyruvate dehydrogenase kinase 4.
Topics: Animals; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Glycogen Synthase Kinase 3 beta; Heart Failure; Hypertension, Pulmonary; Male; Mice; Molecular Docking Simulation; Valsartan; Ventricular Remodeling | 2023 |
Clinical and Hemodynamic Improvement in Pulmonary Hypertension After Switching to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterial Pressure; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Female; Fibrosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Neprilysin; Protease Inhibitors; Pulmonary Artery; Rats, Sprague-Dawley; Tetrazoles; Valsartan; Vascular Remodeling; Ventricular Dysfunction, Right; Ventricular Function, Right; Ventricular Remodeling | 2019 |
Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Hypertension, Pulmonary; Neprilysin; Protease Inhibitors; Recovery of Function; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Waiting Lists | 2020 |
Sacubitril/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Body Weight; Disease Models, Animal; Disease Progression; Drug Combinations; Hypertension, Pulmonary; Hypoxia; Male; Monocrotaline; Rats; Rats, Sprague-Dawley; Tetrazoles; Valsartan | 2021 |
Valsartan attenuates pulmonary hypertension via suppression of mitogen activated protein kinase signaling and matrix metalloproteinase expression in rodents.
Topics: Animals; Blood Pressure; Cell Proliferation; Extracellular Matrix; Fibrosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; MAP Kinase Signaling System; Matrix Metalloproteinases; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Monocrotaline; Phosphorylation; Rats, Sprague-Dawley; Systole; Transforming Growth Factor beta1; Valsartan; Vascular Remodeling | 2017 |
Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure.
Topics: Aminobutyrates; Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Pulmonary Circulation; Rats; Tetrazoles; Valsartan; Vascular Remodeling; Ventricular Dysfunction, Right | 2019 |
Angiotensin II receptor blocker induced fetopathy: 7 cases.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Apgar Score; Benzimidazoles; Biphenyl Compounds; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; Hypertension, Pulmonary; Imidazoles; Infant, Newborn; Kidney; Lung; Male; Oligohydramnios; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Renal Insufficiency; Skull; Tetrazoles; Ultrasonography, Prenatal; Valine; Valsartan | 2011 |